

DO NOT
ENTER AFTER
FINAL DR 7/27/9

Applicants: Wolfe, Michael., et al.
Serial No. 08/984,476

LISTING OF THE CLAIMS:

86. (Currently amended) An isolated polypeptide ~~which consists~~ glucose dependent insulintropic polypeptide (GIP) antagonist consisting essentially of SEQ ID NO:5.

87. (Previously presented) The isolated polypeptide of claim 86 wherein His at position 9 of SEQ ID NO: 5 is replaced with Arg or Lys.

88. (Previously presented) The isolated polypeptide of claim 86 wherein His at position 9 of SEQ ID NO:5 is replaced with Arg.

89. (Previously presented) A composition comprising the isolated polypeptide of claim 86 or claim 88 in a pharmaceutically acceptable vehicle.

90. (Currently amended) A composition comprising ~~the~~ an isolated polypeptide glucose-dependent insulintropic (GIP) antagonist of claim 86 and 88 consisting of the amino acid sequence of SEQ ID NO:5 and an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:5 wherein Arg is at position 9 in a pharmaceutically acceptable vehicle.

91. (Previously presented) The composition of claim 89 or claim 90 further comprising an inert pharmaceutical excipient selected from the group consisting of sweetening, flavoring, coloring, dispersing, disintegrating, binding, granulating, suspending, wetting, preservative and demulcent agents.

92. (Previously presented) The composition of claim 89 wherein the composition is lyophilized.

93. (Withdrawn from consideration) A method of identifying an antagonist of GIP receptor, comprising obtaining a candidate compound, contacting a cell which expresses